Track topics on Twitter Track topics that are important to you
MaxCyte currently has two classes of shares: unrestricted and Regulation S restricted
MaxCyte has dosed the first patient in a Phase I clinical trial to evaluate the safety and effectiveness of intraperitoneal...Read More... The post MaxCyte starts dosing in Phase I trial of MCY-M11 ap...
Swiss gene editing firm CRISPR Therapeutics has signed a non-exclusive commercial licence agreement with US-based drug maker MaxCyte for the...Read More... The post CRISPR and MaxCyte sign licensing d...
Allows Precision to use MaxCyte's Flow Electroporation® technologies to robustly deliver ARCUS genome-editing technology
The study is designed to evaluate MCY-M11, a mesothelin targeting CAR, in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma. MaxCyte CEO Doug Doerfler said: “The in...
The companies have entered into a non-exclusive commercial license agreement that will allow CRISPR Therapeutics to deploy MaxCyte’s Flow Electroporation Technology to develop CRISPR/Cas9-based ther...
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma
Gaithersburg, Maryland – 01 March 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announced today that it has expanded its re...
MEDINET is a world leading company in cell therapy, supporting medical service providers in Japan. Through its service, MEDINET provides medical institutions with advanced technol...
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell the...
MaxCyte is a clinical-stage cell therapeutics company with a growing pipeline of proprietary and partnered drug candidates. Programs in development are based on MaxCyte's platform technology which bre...
We have published hundreds of MEDINET Co., Ltd. and MaxCyte, Inc. news stories on BioPortfolio along with dozens of MEDINET Co., Ltd. and MaxCyte, Inc. Clinical Trials and PubMed Articles about MEDINET Co., Ltd. and MaxCyte, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MEDINET Co., Ltd. and MaxCyte, Inc. Companies in our database. You can also find out about relevant MEDINET Co., Ltd. and MaxCyte, Inc. Drugs and Medications on this site too.
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...